Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, December 15 2022 - 00:58
Hovione and GEA announce a strategic collaboration to advance Continuous Tableting
LISBON, Portugal, Dec. 14, 2022, /PRNewswire-AsiaNet/ --

Hovione and GEA today announced a strategic collaboration to advance Continuous 
Tableting. This partnership stemmed from a successful customer-supplier 
relationship spanning several years. It combines GEA´s engineering expertise 
with Hovione´s development and manufacturing experience and both parties commit 
to partner to accelerate the adoption of Continuous Tableting technology.

The advantages of continuous over batch manufacturing are well known. 
Continuous production systems allow for leaner and risk-reduced development 
paths, leaner supply chains, increased built-in quality, and in general, 
manufacturing processes of greater flexibility and reduced complexity. In the 
context of this strategic collaboration, Hovione and GEA will combine their 
strengths to further advance the technology and contribute to the establishment 
of new standards and new levels of market acceptance.

"Hovione has a track record in industrializing and democratizing emerging 
pharmaceutical technologies, such as amorphous solid dispersions by spray 
drying, and turn them into dependable and scalable offerings that are available 
to all." Says Jean-Luc Herbeaux, CEO of Hovione. He adds "We have been 
committed to Continuous Tableting for the last 7 years and we are now ready to 
contribute decisively to the advancement of one of the most promising 
technologies in pharma manufacturing. This collaboration with GEA, gives us the 
opportunity to link up with a leading designer and supplier of Continuous 
Tableting equipment solutions and bring Continuous Tableting to the next levels 
of reliability, flexibility and adoption." 

Navin Lakhanpaul, Global Head Pharma-Solid Dosage, GEA, adds: "As a leading 
supplier of process technology, GEA has established itself as a trusted 
solution provider in the pharmaceutical industry, and as a pioneer in the 
development of Continuous Tableting technology." He adds "Our relationship with 
Hovione over many years has clearly demonstrated the value in further 
collaborating and developing synergies in our respective areas of expertise. We 
share a common objective of enabling the wider use of Continuous Tableting in 
the Pharmaceutical Industry, and firmly believe that our partnership with 
Hovione will accelerate the growth of this exciting technology."

About Hovione

Hovione is an international company with over 60 years of experience as a 
Contract Development and Manufacturing Organization (CDMO) [ ] 
with a fully integrated offering of services for drug substance, drug product 
intermediate and drug product. The company has four FDA inspected sites [ ] in the USA, Portugal, Ireland and 
China as well as development laboratories in Lisbon, Portugal and New Jersey, 
USA. Hovione provides pharmaceutical customers services for the development and 
compliant manufacture [ 
] of innovative drugs, including highly potent compounds, and customized 
product solutions across the entire drug life cycle. In the inhalation area, 
Hovione is the only independent company offering a complete range of services, 
from API to formulation development and devices. Hovione is a company with a 
culture based on innovation, quality and delivery. Hovione was the first 
Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of 
Rx-360, EFCG and participates actively in industry quality improvement 
initiatives to lead new global industry standards.

About GEA

GEA is one of the world's largest suppliers of systems and components to the 
food, beverage and pharmaceutical industries. The international technology­ 
group, founded in 1881, focuses on machinery and plants, as well as advanced 
process technology, components, and comprehensive services. With more than 
18,000 employees working across five divisions and 62 countries, the group 
generated revenues of more than EUR 4.7 billion in fiscal year 2021. GEA 
plants, processes, components and services enhance the efficiency and 
sustainability of production processes across the globe. They contribute 
significantly to the reduction of CO2 emissions, plastic usage and food waste. 
In doing so, GEA makes a key contribution toward a sustainable future, in line 
with the company's purpose: "Engineering for a better world".

GEA is listed in the German MDAX and the STOXX® Europe 600 Index and is also 
among the companies comprising the DAX 50 ESG and MSCI Global Sustainability 

For more information, please visit or contact:
Vanessa Romeu | Communications Director | |Tel.: +351 21 982 

Photo -
Photo -